CA
RARE icon

Centerpoint Advisors’s Ultragenyx Pharmaceutical RARE Stock Holding History

Centerpoint Advisors’s Portfolio RARE Stock Details RARE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		– Sell
-19
Closed -$1K – 431
2022
Q1 		$1K Hold
19
– – ﹤0.01% 376
2021
Q4 		$2K Buy
+19
New +$1.55K ﹤0.01% 343

Other funds holding RARE

T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
ClearBridge Investments
ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return
Alkeon Capital Management
Alkeon Capital Management New York $59.5B AUM 51.63% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
APM
Avidity Partners Management Dallas, Texas $936M AUM 195% 1-Year Est. Return

Centerpoint Advisors's RARE Position: Q2 2022 in Review

Centerpoint Advisors sold out of Ultragenyx Pharmaceutical (RARE) in Q2 2022, closing a stake of 19 shares — an estimated $1K sold.

Centerpoint Advisors first reported a position in RARE in Q4 2021 and held it in 2 quarters. The position peaked at $2K in Q4 2021. 223 funds tracked by Wall St. Rank hold RARE as of Q2 2022.

  • Centerpoint Advisors reported no remaining Ultragenyx Pharmaceutical position as of Q2 2022 after selling out during the quarter.
  • Centerpoint Advisors sold 19 Ultragenyx Pharmaceutical shares in Q2 2022, an estimated $1K.
  • Centerpoint Advisors first reported a position in Ultragenyx Pharmaceutical in Q4 2021 and held it in 2 quarters.
  • Centerpoint Advisors's Ultragenyx Pharmaceutical position peaked at $2K in Q4 2021.
  • 223 funds tracked by Wall St. Rank held Ultragenyx Pharmaceutical as of Q2 2022.

Based on Centerpoint Advisors's 13F filing for Q2 2022, filed 18 Jul 2022.